节点文献

骨肉瘤化疗耐药相关机制的研究进展

Advance in pathogenesis of chemotherapy resistance of osteosarcoma

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 陈金泉张世权

【Author】 CHEN Jin-quan;ZHANG Shi-quan;Musculoskeletal Tumor Center, Shenzhen Second People’s Hospital, the first Affiliated Hospital of Shenzhen University Health Science Center;

【机构】 深圳市第二人民医院、深圳大学医学院第一附属医院骨肿瘤中心广州医科大学研究生院

【摘要】 <正>骨肉瘤(osteosarcoma,OS)是最常见的原发性恶性骨肿瘤,约占全部骨肿瘤的15%,好发于儿童和青少年[1]。OS的传统治疗方法主要是高位截肢治疗,随着影像学、辅助化疗、外科技术及生物力学工程学的发展,自20世纪80年代以来,OS的治疗由单纯高位截肢术发展为以保肢手术、新辅助化疗相结合的综合保肢治疗,OS患者的截肢率显著降低、5年生存率较过往有所提高,然而,尽

【Abstract】 Osteosarcoma is the most common primary cancer derived from bone tissues, which is frequently found in adolescents and children. The extensive application of the comprehensive limb salvage treatment reduces the amputation rate significantly, and the five-year survival rate is higher. But the prognosis of chemotherapy-resistant patients is still poor. It is very important to improve the prognosis of osteosarcoma by clarifying the pathogenesis of drug resistance. In this paper, we review the mechanism of osteosarcoma chemoresistance, including the non-coding RNA disorders, gene, DNA repair, cancer stem cells, autophagy and tumor microenvironment ect. We also summarize the deficiencies in the current studies about osteosarcoma chemoresistance and hope to improve osteosarcoma chemotherapy sensitivity.

【基金】 深圳市知识创新计划基础研究项目(JCYJ20130401112006994)
  • 【文献出处】 中国骨与关节杂志 ,Chinese Journal of Bone and Joint , 编辑部邮箱 ,2017年12期
  • 【分类号】R738.1
  • 【被引频次】4
  • 【下载频次】367
节点文献中: 

本文链接的文献网络图示:

本文的引文网络